LIXTW

Lixte Biotechnology Holdings, Inc. is a drug discovery company. The Company uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. It's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and includes two categories of compounds at various stages of pre-clinical and clinical development. It is developing two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of novel structures, which may be useful in the treatment of not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds which may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases.